Clinical Experience with CD3 X CD19 Bispecific Antibodies in Patients with B Cell Malignancies

Journal of Hematotherapy and Stem Cell Research

Volumn 4, Issue 5, 1995, Pages 433-437

  de Gast, Gijsbert C ^a   Van Houten, Anja A ^a   Haagen, Inez Anne ^b   Klein, Sigrid ^b   de Weger, Roel A ^b   Van Dijk, Anet ^a   Phillips, Jenny ^c   Clark, Mike ^c   Bast, Bert J e g ^b  

^a Departments of 'Hematology ^*  (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CD19 ANTIGEN; CD3 ANTIGEN; INTERLEUKIN 2;

B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CASE REPORT; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CONFERENCE PAPER; DRUG EFFECT; DRUG SCREENING; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE ACTIVATION;

ANIMAL; ANTIBODIES, BISPECIFIC; ANTIBODY SPECIFICITY; ANTIGENS, CD19; B-LYMPHOCYTES; BIOLOGICAL RESPONSE MODIFIERS; COMBINED MODALITY THERAPY; FEVER; HUMAN; INTERLEUKIN-2; LEUKEMIA, B-CELL, CHRONIC; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; MICE; MUROMONAB-CD3; RATS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR; TUMOR STEM CELLS;

EID: 0028824721     PISSN: 15258165     EISSN: none     Source Type: Journal    
DOI: 10.1089/scd.1.1995.4.433     Document Type: Article

References (11)

1. Weiner, G.J. & De Gast, G.C. Bispecific monoclonal antibody therapy of b-cell malignancy. Leukemia Lymphoma 16:199, 1995.
2. Haagen, I-A., Van de Griend, R.J., Clark M., et al. Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (aCD3/aCD19). Clin. Exp. Immunol. 90: 368, 1992.
3. Haagen, I-A, Geerars, A, De Lau, W.B., et al. KiUing of autologous B-lineage malignancy using CD3 X CD19 bispecific monoclonal antibody in end-stage leukemia and lymphoma. Blood 84:556, 1994.
4. Haagen, I-A., Geerars, A.J.G., Bast, E.J.E.G., et al. Evaluation of Fey receptor-mediated T cell activation by two purified CDS X CD 19 bispecific monoclonal antibodies with hybrid Fc domains. Ther. Immunol. 1:279, 1994.
5. Haagen, I-A., De Lau, W.B.M., Bast B.J.E.G., et al. Unprimed CD4+ and CD8+ T cells can be rapidly activated by CD3 X CD 19 bispecific antibody to proliferate and become cytotoxic. Cancer Immunol. Immunother. 39:391, 1994.
6. Haagen, I-A., Geerars, A.J.G., De Lau, W.B.M., et al. The efficacy of CD3 X CD 19 BsAb in a clonogenic assay: The effect of repeated addition of bispecific antibody and IL. Blood 85:3208, 1995.
7. De Gast, G.C., Haagen, I-A., Van Houten, A.A., et al. CD8 T cell activation after intravenous administration of CD3 X CD 19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol. Immunother. 40:390, 1995.
8. Weiner, G.J. Bispecific IgG and IL-2 therapy of a syngeneic B-cell lymphoma in immunodeficient mice. Int. J. Cancer 7:63, 1992.
9. Bohlen, H., Hopff, T., Manzke, O., et al. Lysis of malignant B-cells from patients with B-chronic lymphocytic leukemia by autologous T-cells activated with CD3 X CD 19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood 82:1803, 1993.
10. Bohlen, H. Manzke, O., Patel, B., et al. Cytolysis of leukemia B cells by T cells activated via 2 bispecific antibodies. Cancer Res. 53:4310, 1993.
11. O'Brien, S., Kantarjian, H., Beran, M., et al. Results of flu-darabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 82:1695, 1993.